Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Sep-23-13 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Clinical Research | 2,923.0 | 2,813.0 | 2,622.4 | 2,168.9 | | 1,375.8 | | |
| Data Solutions | 260.3 | 253.3 | 249.5 | 90.5 | | | | |
| Other | | | | | | 238.0 | | |
| Total revenues [+] | 3,183.4 | 3,066.3 | 2,871.9 | 2,259.4 | 502.5 | 1,613.9 | 1,459.6 | 379.2 |
| Services | | | | | | 1,375.8 | 1,266.6 | 324.4 |
| Reimbursements | | | | | | 238.0 | 193.0 | |
| Revenue growth [+] | 3.8% | 6.8% | 27.1% | 349.6% | -68.9% | 10.6% | | |
| Clinical Research | 3.9% | 7.3% | 20.9% | | | | | |
| Data Solutions | 2.8% | 1.5% | 175.7% | | | | | |
| Cost of goods sold [+] | 2,270.3 | 2,191.5 | 2,106.4 | 1,682.6 | 0.0 | 1,124.6 | 1,052.2 | 222.8 |
| Reimbursable costs | | | | | | 238.0 | 193.0 | |
| Direct costs | | | | | | 886.5 | 859.2 | |
| Gross profit | 913.1 | 874.8 | 765.5 | 576.8 | 502.5 | 489.3 | 407.4 | 156.4 |
| Gross margin | 28.7% | 28.5% | 26.7% | 25.5% | 100.0% | 30.3% | 27.9% | 41.3% |
| Selling, general and administrative | 453.0 | 394.9 | 371.8 | 322.0 | 269.9 | 246.4 | 254.0 | 69.7 |
| Equity in earnings | | | 0.1 | 0.1 | 2.8 | -3.4 | 2.0 | 0.6 |
| Other operating expenses | | | | | | | | 84.0 |
| EBITDA [+] | 460.0 | 479.9 | 393.8 | 254.9 | 235.4 | 239.5 | 155.5 | 3.3 |
| EBITDA growth | -4.1% | 21.9% | 54.5% | 8.3% | -1.7% | 54.1% | | |
| EBITDA margin | 14.5% | 15.7% | 13.7% | 11.3% | 46.8% | 14.8% | 10.7% | 0.9% |
| Depreciation | 55.3 | 46.3 | 40.6 | 29.0 | 24.1 | 21.3 | 22.2 | 25.3 |
| EBITA | 404.7 | 433.6 | 353.2 | 225.9 | 211.3 | 218.3 | 133.3 | -22.0 |
| EBITA margin | 12.7% | 14.1% | 12.3% | 10.0% | 42.0% | 13.5% | 9.1% | -5.8% |
| Amortization of intangibles | 76.3 | 68.6 | 71.6 | 49.2 | 45.4 | 56.7 | 74.4 | |
| EBIT [+] | 328.4 | 365.0 | 281.6 | 176.7 | 165.9 | 161.6 | 58.9 | -22.0 |
| EBIT growth | -10.0% | 29.6% | 59.3% | 6.5% | 2.7% | 174.3% | | |
| EBIT margin | 10.3% | 11.9% | 9.8% | 7.8% | 33.0% | 10.0% | 4.0% | -5.8% |
| Non-recurring items [+] | 0.3 | 1.1 | 0.1 | 0.4 | 0.8 | 0.7 | 0.0 | |
| Loss (gain) on sale of assets | 0.3 | 1.1 | 0.1 | 0.4 | 0.8 | 0.7 | 0.0 | |
| Interest expense | 43.1 | 52.0 | 57.4 | 46.7 | 54.9 | 54.6 | 81.9 | 23.7 |
| Interest expense | 43.1 | 52.0 | 57.4 | 46.7 | 54.9 | 54.6 | 81.9 | 23.7 |
| Other income (expense), net [+] | -26.0 | -6.0 | -2.5 | -55.1 | -16.3 | 8.9 | -18.8 | -11.4 |
| Gain (loss) on debt retirement | | | | | -38.2 | | -25.0 | |
| Gain (loss) on foreign currency transactions | -25.5 | -2.3 | -1.0 | -39.6 | 24.0 | 14.0 | 10.5 | |
| Other | 0.0 | 0.2 | -0.4 | -0.3 | 0.6 | -1.4 | -2.3 | 1.2 |
| Pre-tax income | 259.0 | 305.9 | 221.5 | 74.5 | 93.9 | 115.2 | -41.9 | -57.1 |
| Income taxes | 62.0 | 62.8 | 67.2 | -12.6 | 28.5 | 30.0 | -8.2 | -17.2 |
| Tax rate | 23.9% | 20.5% | 30.3% | | 30.3% | 26.1% | 19.5% | 30.1% |
| Minority interest | | 0.1 | 0.6 | 0.4 | | | | |
| Net income | 197.0 | 243.0 | 153.9 | 86.9 | 68.2 | 81.8 | -35.7 | -39.9 |
| Net margin | 6.2% | 7.9% | 5.4% | 3.8% | 13.6% | 5.1% | -2.4% | -10.5% |
| |
| Basic EPS [+] | $3.11 | $3.77 | $2.40 | $1.39 | $1.12 | $1.36 | ($0.83) | ($1.02) |
| Growth | -17.4% | 57.0% | 72.4% | 24.1% | -17.7% | -263.7% | | |
| Diluted EPS [+] | $3.04 | $3.68 | $2.32 | $1.32 | $1.06 | $1.29 | ($0.83) | ($1.02) |
| Growth | -17.4% | 58.7% | 75.5% | 24.9% | -18.2% | -255.3% | | |
| |
| |
| Shares outstanding (basic) [+] | 63.4 | 64.5 | 64.1 | 62.4 | 60.8 | 60.0 | 42.9 | 39.3 |
| Growth | -1.8% | 0.6% | 2.7% | 2.8% | 1.3% | 39.8% | | |
| Shares outstanding (diluted) [+] | 64.8 | 66.0 | 66.3 | 65.8 | 64.5 | 63.2 | 42.9 | 39.3 |
| Growth | -1.9% | -0.5% | 0.9% | 2.0% | 2.0% | 47.3% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|